Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.35 |
| ▸ | PDE4A | P27815 | 6/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21797098 | 0.84 | CHRM3 (0.41) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL13033012 | 0.84 | PDE10A (0.50) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL21211777 | 0.77 | PDE10A (0.43) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL24500132 | 0.77 | PDE10A (0.43) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL15948039 | 0.76 | CHRM3 (0.38) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL18069346 | 0.76 | PDE10A (0.41) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL28979288 | 0.76 | HTT (0.43) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL28301853 | 0.75 | PDE10A (0.42) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL3208618 | 0.75 | PDE10A (0.42) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL5226624 | 0.75 | PDE10A (0.42) | PDE10ACHRM3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | PDE10A 2164/4885CHRM3 3349/4885PDE4A 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.